Breast Cancer

Endocrine Therapy

ER/PR-POSITIVE HER2 NEGATIVE

IRB# 6256-ISPY2 Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging and Molecular Analysis 2

HER2 POSITIVE

“TRIPLE NEGATIVE” EP/PR –NEGATIVE HER2-NEGATIVE

CDK 4/6i + PARPi

Pre-Op Therapy

Surgical Therapy

Adjuvant Therapy

1st line MBC Therapy

2nd line MBC Therapy

3rd line MBC Therapy

"Heavily Pre-treated” Therapy

No Trial Currently Available

IRB# 17504 MonarchE: Endocrine Therapy With or Without Abemaciclib Following Surgery in Participants with Breast Cancer

No Trials Currently Available

IRB# 19200 DS-8201a Compared to Treatment of Physician’s Choice for HER2-low Unresectable /Metastatic Breast Cancer

IRB# 19358 Elacestrant Monotherapy vs. SOC for Advanced BC following CDK/6 Inhibitor Therapy

IRB# 17887 SGN-LIV1A Part E

IRB # 17887 A Safety study of SGN-LIV1A Part D

IRB# 19078 S1501: Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic HER-2+ Breast Cancer, Phase III

IRB 15588 SMMART

IRB# 17461 S1418 A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy

IRB# 18540 Phase 2 Olaparib and Durvalumab in Patients with Metastatic Triple Negative Breast Cancer

IRB# 19200 DS-8201a vs. Physician’s Choice for HER2-low Unresectable /Metastatic BC

IRB# 15366 Tucatinib vs. Placebo in Combination with Capecitabine & Trastuzumab

IRB# 19358 MonarchE: Endocrine Therapy With or Without Abemaciclib Following Surgery in Participants with Breast Cancer

IRB# 15588 SMMART

http://www.ohsu.edu/research/rda/so/knight.php

03/29/2019